Clinical Trial Update: Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating trastuzumab with chemo- and immunotherapy as first-line treatment for HER2-positive esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Trastuzumab (trastuzumab)

Snippet

Sponsor: Morten Mau-Sørensen | Conditions: Esophageal Squamous Cell Carcinoma, HER-2 Protein Overexpression | Phase 2 | Status: UNKNOWN